胃食管反流病药物治疗进展

Clinical effects of esomeprazole combined with mosapride for treatment of gastroesophageal reflux disease

AIM: To explore the clinical effects of esomeprazole combined with mosapride in the treatment of gastroesophageal reflux disease.

METHODS: One hundred and sixteen patients with gastroesophageal reflux disease were randomly divided into either an observation group or a control group. The observation group was treated by esomeprazole combined with mosapride, and the control group was treated by esomeprazole alone. The scores of gastroesophageal reflux disease-Q (GERD-Q), the rate of Helicobacter pylori (H. pylori) infection and the effective rate were compared for the two groups.

RESULTS: The scores of GERD-Q at 2, 4, and 8 wk post treatment were lower than that prior treatment (15.80 ± 2.32, 11.80 ± 1.88, 10.94 ± 1.32 vs 19.23 ± 2.75; 17.02 ± 2.06, 13.52 ± 1.77, 11.41 ± 1.46 vs 19.56 ± 2.55; P < 0.05). There were no significant differences in the scores of GERD-Q among different time points (19.23 ± 2.75 vs 19.56 ± 2.55, 15.80 ± 2.32 vs 17.02 ± 2.06, 11.80 ± 1.88 vs 13.52 ± 1.77, 10.94 ± 1.32 vs 11.41 ± 1.46, P > 0.05). The effective rate for the observation group was significantly higher than that for the control group (82.76% vs 65.52%, P < 0.05). The rates of H. pylori infection post treatment for the two groups were lower than those prior treatment (17.24% vs 48.28%, 24.14% vs 50.00%, P < 0.05). There was no significant difference in the rate of H. pylori infection post treatment between the two groups (17.24% vs 24.14%, P > 0.05).

CONCLUSION: Esomeprazole combined with mosapride has good clinical effects in the treatment of gastroesophageal reflux disease with regards to improved effective rate, scores of GERD-Q, and reduced rate of H. pylori infection.

Weisu granules combined with conventional Western medicines for treatment of gastroesophageal reflux disease

AIM: To explore the clinical effects of Weisu granules combined with conventional Western medicines in the treatment of gastroesophageal reflux disease (GERD).

METHODS: Eighty-four patients with GERD were randomly divided into either an experiment group or a control group. Both the control and experiment groups were treated with conventional Western medicines, and the experiment group was additionally treated with Weisu granules. Symptom score, endoscopic score, and clinical effects were compared for the two groups.

RESULTS: Symptom score and endoscopic score were significantly lower post treatment than prior treatment in both groups (7.47 ± 2.51 vs 18.96 ± 2.88, 11.49 ± 2.35 vs 19.72 ± 2.79, 1.49 ± 0.61 vs 2.49 ± 0.62, 1.64 ± 0.63 vs 2.47 ± 0.69; P < 0.05). Symptom score and endoscopic score post treatment were significantly lower in the experiment group than in the control group (7.47 ± 2.51 vs 1.49 ± 0.61, 11.49 ± 2.35 vs 1.64 ± 0.63, P < 0.05). The clinical effects with regard to symptom improvement were better in the experiment group than in the control group (95.24% vs 80.95%, P < 0.05); there was no significant difference in clinical effects with regard to endoscopic improvement (78.57% vs 71.43%, P > 0.05).

CONCLUSION: Weisu granules combined with conventional Western medicines in GERD can improve clinical symptoms and clinical effects, and can be a treatment of choice for elderly patients with GERD.

Symptomatic gastroesophageal reflux disease among Uygur residents in Urumqi: An epidemiological study and preventive treatment

AIM: To explore the prevalence of symptomatic gastroesophageal reflux disease (GERD) and reflux esophagitis (RE) in a Uygur adult population in Urumqi, to identify the risk factors for GERD, and to explore the preventive treatment of this disease in some patients.

METHODS: A total of 3000 Uygur residents aged from 18 to 78 years old were studied, and 2980 patients completed the study. This study was performed by clustering, stratifying and simple random sampling. Symptom scores were calculated using the GerdQ scale (the highest score is 18). GerdQ score ≥ 8 indicated the presence of symptomatic GERD. Subjects with a GerdQ score ≥ 8 were included in the observation group, and those with a GerdQ score < 8 were assigned to the control group. A case-control study was also performed in some subjects to confirm the diagnosis of GERD and RE. Multivariable logistic regression analysis was performed to analyze risk factors for GERD. In addition, 53 subjects with GERD were divided into an esomeprazole group, a cimetidine group, and a lifestyle changes group to receive 4 weeks of treatment, and the treatment effects were compared.

RESULTS: Of 2980 subjects who completed the survey, 468 (15.6%) had symptomatic GER (GerdQ score ≥ 8), and the male-to-female ratio was 1.07:1. The correct incidence was 72.86%. Estimated prevalence for GERD and RE was 11.44% and 2.92%, respectively. High-fat diet (OR = 7.964), drinking (OR = 3.804), drinking strong tea (OR = 2.758), abdominal obesity (OR = 2.713), greasy food (OR = 2.408) and Helicobacter pylori infection (OR = 0.186) were factors associated with the development of GERD. The rates of symptom improvement for the esomeprazole group, cimetidine group and lifestyle change group were 88.24%, 47.06% and 26.32%, respectively.

CONCLUSION: GERD is a multi-factorial disease. High-fat diet, drinking, drinking strong tea, abdominal obesity, and greasy food are risk factors for GERD, while Helicobacter pylori infection is a protective factor for GERD. Changing eating habits and lifestyle is helpful in controlling GERD.

Efficacy of combined aluminum magnesium carbonate, esomeprazole and Deanxit in treatment of gastroesophageal reflux disease in young or middle-aged patients with anxiety: An analysis of 60 cases

AIM: To evaluate the efficacy of combined aluminum magnesium carbonate, esomeprazole and Deanxit in the treatment of gastroesophageal reflux disease in young or middle-aged patients with clinical anxiety.

METHODS: One hundred and eighty young or middle-aged patients were randomly and equally divided into three groups: A, B and C. Group A was treated with aluminum magnesium carbonate, esomeprazole and Deanxit, group B was treated with esomeprazole and Deanxit, and group C was treated with aluminum magnesium carbonate and Deanxi. Clinical remission, extent of repair of the esophageal and gastric mucosa and adverse reactions were compared between the three groups.

RESULTS: After treatment, the number of responders was 58 (96.67%) in group A, 49 (81.67%) in group B, 37 (61.67%) in group C, and the number of patients developing recurrence in the three groups was 1, 8 and 23, respectively. The total response rate, recurrence rate, the extent of repair of the esophageal and gastric mucosa, and the incidence of adverse reactions were better in group A than in groups B and C (all P < 0.05).

CONCLUSION: Combined aluminum magnesium carbonate, esomeprazole and Deanxit are effective in the treatment of gastroesophageal reflux disease with anxiety in terms of symptom relief and repair of the esophageal and gastric mucosa.